DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Desbuquois dysplasia — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDesbuquois dysplasia maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for desbuquois dysplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
calcium activated nucleotidase 1 (CANT1) — CANT1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gp2drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1S1D · 1.6 Å · ligand PHOSPHOMETHYLPHOSPHONIC ACID GUANOSYL ESTER (GP2). Experimental structure, not a prediction.
What the evidence adds up to
Desbuquois dysplasia is a rare autosomal recessive skeletal disorder with two recognised genetic forms. A 2024 review of 111 published case reports found that DBQD1, linked to biallelic mutations in CANT1, accounted for 54 cases, while DBQD2, caused by mutations in either CANT1 or XYLT1, accounted for 39 cases. A further 14 cases were classified as the Kim variant. The median birth weight in this cohort was 2505 g, median length 40 cm, and median occipitofrontal circumference 33 cm. Over 35% of cases involved missense mutations, primarily in CANT1, and approximately 60% of patients had a history of parental consanguinity. Many mutations produced premature stop codons and truncated, likely nonfunctional proteins.
A 2019 case report describes whole exome sequencing enabling early prenatal diagnosis of Desbuquois dysplasia type 1 before characteristic ultrasound signs appeared. The condition is described as very severe and sometimes lethal, with prenatal onset of severe micromelic short stature, joint laxity with multiple dislocations, specific radiographic features, and facial dysmorphism. A 2009 case report of a three-year-old girl from a consanguineous Austrian family documents additional findings including synophyrs, curly eyelashes, pterygium colli, and early patellar ossification, noting that the phenotypic variability can cause diagnostic confusion but that distinctive radiographic features are virtually diagnostic.
No therapeutic interventions are described in any of these reports. The 2024 review calls for continued research to uncover underlying mechanisms and improve outcomes through targeted treatments, but no such treatments currently exist. What is missing is any clinical trial data, any drug tested in this population, any animal model work testing a specific compound, and any patient stratification beyond genetic subtype. The evidence base remains entirely descriptive, with no interventional studies and no survival data beyond the observation that the condition can be lethal early in life.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Molecular Sciences · 2024 · 8 citations · open access
Clinical and Genetic Insights into Desbuquois Dysplasia: Review of 111 Case Reports
AbstractSkeletal disorders encompass a wide array of conditions, many of which are associated with short stature. Among these, Desbuquois dysplasia is a rare but severe condition characterized by profound dwarfism, distinct facial features, joint hypermobility with multiple dislocations, and unique vertebral and metaphyseal anomalies. Desbuquois dysplasia is inherited in an autosomal recessive manner, with both the DBQD1 (MIM 251450) and DBQD2 (MIM 615777) forms resulting from biallelic mutations. Specifically, DBQD1 is associated with homozygous or compound heterozygous mutations in the CANT1 gene, while DBQD2 can result from mutations in either the CANT1 or XYLT1 genes. This review synthesizes the findings of 111 published case reports, including 54 cases of DBQD1, 39 cases of DBQD2, and 14 cases of the Kim variant (DDKV). Patients in this cohort had a median birth weight of 2505 g, a median length of 40 cm, and a median occipitofrontal circumference of 33 cm. The review highlights the phenotypic variations across Desbuquois dysplasia subtypes, particularly in facial characteristics, joint dislocations, and bone deformities. Genetic analyses revealed a considerable diversity in mutations, with over 35% of cases involving missense mutations, primarily affecting the CANT1 gene. Additionally, approximately 60% of patients had a history of parental consanguinity, indicating a potential genetic predisposition in certain populations. The identified mutations included deletions, insertions, and nucleotide substitutions, many of which resulted in premature stop codons and the production of truncated, likely nonfunctional proteins. These findings underscore the genetic and clinical complexity of Desbuquois dysplasia, highlighting the importance of early diagnosis and the potential for personalized therapeutic approaches. Continued research is essential to uncover the underlying mechanisms of this disorder and improve outcomes for affected individuals through targeted treatments.
The Journal of Maternal-Fetal & Neonatal Medicine · 2019 · 8 citations
Prenatal diagnosis of Desbuquois dysplasia type 1 by whole exome sequencing before the occurrence of specific ultrasound signs
AbstractDesbuquois dysplasia is a very severe and sometimes lethal form of osteochondrodysplasia characterized by prenatal onset of severe micromelic short stature, joint laxity with multiple joint dislocations, specific radiographic features, and facial dysmorphism. Here, we report a case for which whole exome sequencing allowed early prenatal diagnosis of Desbuquois dysplasia before the detection of characteristic ultrasound signs of the disease.
Synophyrs, curly eyelashes and Ptyrigium colli in a girl with Desbuquois dysplasia: a case report and review of the literature
AbstractINTRODUCTION: Desbuquois dysplasia is a rare, but well described syndrome with remarkable clinical and radiographic variability ranging from mild skeletal involvement with normal intelligence to those with early fatal outcome. CASE PRESENTATION: Distinctive radiographic features of Desbuquois dysplasia-typical hand type have been documented in a 3-year-old girl. Synophyrs, curly eyelashes and ptyrigium colli were additional findings. CONCLUSION: The phenotypic variability of Desbuquois syndrome might be an element of diagnostic confusion. However, distinctive radiographic features should urgently requiring attention and are virtually diagnostic. We report what might be the first clinical report of Desbuquois dysplasia from a consanguineous family in Austria. Unusual facial dysmorphism resembling Cornelia-De Lange syndrome and early patellar ossification were additional unreported features in connection with Desbuquois dysplasia.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
